Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Trimmed by Orion Capital Management LLC

Orion Capital Management LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 419 shares of the medical research company’s stock after selling 35 shares during the quarter. Orion Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $222,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Iyo Bank Ltd. increased its position in Thermo Fisher Scientific by 12.4% in the fourth quarter. Iyo Bank Ltd. now owns 9,069 shares of the medical research company’s stock worth $4,814,000 after buying an additional 1,000 shares during the period. ICW Investment Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 5.1% in the 4th quarter. ICW Investment Advisors LLC now owns 912 shares of the medical research company’s stock worth $484,000 after acquiring an additional 44 shares during the period. Phraction Management LLC lifted its position in Thermo Fisher Scientific by 32.8% in the 4th quarter. Phraction Management LLC now owns 27,463 shares of the medical research company’s stock valued at $14,577,000 after purchasing an additional 6,784 shares during the last quarter. Cary Street Partners Asset Management LLC grew its position in Thermo Fisher Scientific by 39.0% in the 4th quarter. Cary Street Partners Asset Management LLC now owns 5,228 shares of the medical research company’s stock worth $2,775,000 after purchasing an additional 1,467 shares during the last quarter. Finally, Sivik Global Healthcare LLC raised its holdings in shares of Thermo Fisher Scientific by 14.3% during the fourth quarter. Sivik Global Healthcare LLC now owns 12,000 shares of the medical research company’s stock valued at $6,369,000 after buying an additional 1,500 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Up 2.2 %

Shares of NYSE:TMO traded up $12.76 during midday trading on Wednesday, reaching $581.48. The company had a trading volume of 724,506 shares, compared to its average volume of 1,543,467. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The firm has a market cap of $221.96 billion, a price-to-earnings ratio of 36.48, a price-to-earnings-growth ratio of 2.40 and a beta of 0.80. The company has a fifty day simple moving average of $574.58 and a two-hundred day simple moving average of $531.67.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.59 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent analyst reports. The Goldman Sachs Group increased their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. Royal Bank of Canada upped their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. HSBC upped their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Raymond James boosted their price objective on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $607.35.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last quarter, insiders have sold 52,277 shares of company stock valued at $29,649,264. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.